EDAP TMS Strengthens Market Position with Landmark HIFI-2 Data Supporting Focal One ® Robotic HIFU in Radiorecurrent Prostate Cancer. AUSTIN, ...
Edap Tms (NASDAQ:EDAP) reported what management described as a “strong first quarter” for 2026, highlighted by record first-quarter revenue and continued momentum in its high-intensity focused ...
Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...
3hon MSN
EDAP reiterates 2026 core HIFU revenue of $50M-$54M as US procedures grow 53% year-over-year
Q1 2026 Management View “As announced this morning, we delivered a strong first quarter. We reported record first quarter total revenue for the company of $17.8 million, led by record first quarter ...
Appointment signals next phase of expansion for HIFU-based prostate care as demand grows for non-invasive, ...
EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue 53% Growth in First Quarter U.S. HIFU Procedures Year-Over-Year 83% Growth in First Quarter Focal One Shipments ...
SAN ANTONIO -- A comparison of high-intensity focused ultrasound (HIFU) and radical prostatectomy (RP) found that HIFU was non-inferior to surgery as primary treatment for localized prostate cancer, ...
Hemiablation HIFU for Prostate Cancer Data confirm that HIFU is not a safe option for patjents with high-risk prostate cancer. Whole gland high-intensity focused ultrasound (HIFU) therapy is less ...
UCSF Health has performed 150 robotic focal high-intensity focused ultrasound (HIFU) procedures for patients living with prostate cancer, becoming the first on the West Coast and the first UC Health ...
HIFU treatment failure is more likely when there is cancer involvement at the prostate base. PSMA PET/CT may improve lesion detection and patient selection for focal therapy. The locations of prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results